Sardanelli F, Magni V, Rossini G, Kilburn-Toppin F, Healy N, Gilbert F
Insights Imaging. 2024; 15(1):96.
PMID: 38536530
PMC: 10973307.
DOI: 10.1186/s13244-024-01653-4.
Pawlak M, Rudnicki W, Borkowska A, Skubisz K, Rydzyk R, Luczynska E
Biomedicines. 2023; 11(12).
PMID: 38137447
PMC: 10741119.
DOI: 10.3390/biomedicines11123226.
Kubota K, Nakashima K, Nakashima K, Kataoka M, Inoue K, Goto M
Breast Cancer. 2023; 31(2):157-164.
PMID: 37973686
PMC: 10901949.
DOI: 10.1007/s12282-023-01521-x.
Gamble L, McClelland P, Teke M, Samaranayake S, Juneau P, Famiglietti A
NPJ Breast Cancer. 2023; 9(1):77.
PMID: 37758801
PMC: 10533560.
DOI: 10.1038/s41523-023-00585-4.
de Jong D, Desperito E, Al Feghali K, Dercle L, Seban R, Das J
J Clin Med. 2023; 12(13).
PMID: 37445572
PMC: 10342839.
DOI: 10.3390/jcm12134537.
The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers.
Obdeijn I, Mann R, Loo C, Lobbes M, Voormolen E, van Deurzen C
Breast Cancer Res Treat. 2020; 181(3):581-588.
PMID: 32333294
PMC: 7220868.
DOI: 10.1007/s10549-020-05642-1.
Improving the diagnostic accuracy of a stratified screening strategy by identifying the optimal risk cutoff.
Brinton J, Hendrick R, Ringham B, Kriege M, Glueck D
Cancer Causes Control. 2019; 30(10):1145-1155.
PMID: 31377875
PMC: 6736710.
DOI: 10.1007/s10552-019-01208-9.
International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.
Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino W
Br J Cancer. 2019; 121(1):15-21.
PMID: 30971774
PMC: 6738089.
DOI: 10.1038/s41416-019-0446-1.
Contrast-enhanced MRI for breast cancer screening.
Mann R, Kuhl C, Moy L
J Magn Reson Imaging. 2019; 50(2):377-390.
PMID: 30659696
PMC: 6767440.
DOI: 10.1002/jmri.26654.
Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer.
Huzarski T, Gorecka-Szyld B, Huzarska J, Psut-Muszynska G, Wilk G, Sibilski R
Hered Cancer Clin Pract. 2017; 15:4.
PMID: 28265306
PMC: 5333437.
DOI: 10.1186/s13053-017-0064-y.
Applying a computer-aided scheme to detect a new radiographic image marker for prediction of chemotherapy outcome.
Wang Y, Qiu Y, Thai T, Moore K, Liu H, Zheng B
BMC Med Imaging. 2016; 16(1):52.
PMID: 27581075
PMC: 5006425.
DOI: 10.1186/s12880-016-0157-5.
Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality.
Evans D, Harkness E, Howell A, Wilson M, Hurley E, Holmen M
Hered Cancer Clin Pract. 2016; 14:8.
PMID: 27087880
PMC: 4832454.
DOI: 10.1186/s13053-016-0048-3.
Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis.
Phi X, Saadatmand S, de Bock G, Warner E, Sardanelli F, Leach M
Br J Cancer. 2016; 114(6):631-7.
PMID: 26908327
PMC: 4800299.
DOI: 10.1038/bjc.2016.32.
MRI screening for breast cancer in women at high risk; is the Australian breast MRI screening access program addressing the needs of women at high risk of breast cancer?.
Schenberg T, Mitchell G, Taylor D, Saunders C
J Med Radiat Sci. 2015; 62(3):212-25.
PMID: 26451244
PMC: 4592676.
DOI: 10.1002/jmrs.116.
[The place of magnetic resonance imaging in lobular carcinoma of the breast].
Bouzoubaa W, Laadioui M, Alaoui F, Jayi S, Bouguern H, Chaara H
Pan Afr Med J. 2014; 18:21.
PMID: 25368710
PMC: 4214568.
DOI: 10.11604/pamj.2014.18.21.4055.
Challenging and complex decisions in the management of the BRCA mutation carrier.
Stan D, Shuster L, Wick M, Swanson C, Pruthi S, Bakkum-Gamez J
J Womens Health (Larchmt). 2013; 22(10):825-34.
PMID: 23987739
PMC: 4047843.
DOI: 10.1089/jwh.2013.4407.
Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.
Pataky R, Armstrong L, Chia S, Coldman A, Kim-Sing C, McGillivray B
BMC Cancer. 2013; 13:339.
PMID: 23837641
PMC: 3711845.
DOI: 10.1186/1471-2407-13-339.
Importance of revealing a rare case of breast cancer in a female to male transsexual after bilateral mastectomy.
Nikolic D, Djordjevic M, Granic M, Nikolic A, Stanimirovic V, Zdravkovic D
World J Surg Oncol. 2013; 10:280.
PMID: 23273269
PMC: 3554459.
DOI: 10.1186/1477-7819-10-280.
Breast dynamic contrast-enhanced examinations with fat suppression: are contrast-agent uptake curves affected by magnetic field inhomogeneity?.
Schmidt M, Borri M, Scurr E, Ertas G, Payne G, OFlynn E
Eur Radiol. 2012; 23(6):1537-45.
PMID: 23242002
DOI: 10.1007/s00330-012-2735-4.
Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers.
Schackmann E, Munoz D, Mills M, Plevritis S, Kurian A
Fam Cancer. 2012; 12(1):65-73.
PMID: 23086584
PMC: 4827615.
DOI: 10.1007/s10689-012-9577-8.